We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
1
Sep 2026
Immediate coronary angiography did not improve 30-day survival compared with a deferred strategy in patients without an ECG ST-elevation after out-of-hospital cardiac arrest.
1
Sep 2026
The American Academy of Neurology (AAN) has launched BrainHealth.com, a new public resource offering expert-reviewed information, tools and stories to help people improve and protect their brain health.
1
Sep 2026
Results from a clinical trial funded by the National Institutes of Health (NIH) and published today in the journal Lancet Infectious Diseases show that the antiviral drug, PAXLOVID, commonly prescribed to treat acute COVID-19, does not have an impact on Long COVID symptoms when compared to placebo.
1
Sep 2026
A therapeutic approach pioneered in Mainz for the treatment of multiple sclerosis (MS) is taking an important step toward clinical application.